Abstract 1350P
Background
Osimertinib is a standard treatment for pts with EGFR-mt NSCLC and is highly effective for BMs. It is unclear whether upfront LT for BMs prolong survival of pts with EGFR-mt NSCLC. The aim of this study was to reveal the survival benefit of upfront LT for BMs in pts with EGFR-mt NSCLC treated with osimertinib.
Methods
We conducted a multicenter (9 centers in Japan), retrospective cohort study of consecutive pts with EGFR-mt NSCLC who had BMs before the initiation of osimertinib between August 2018 and October 2021. Pts with meningitis were excluded. We divided all pts into two groups: pts who received upfront LT for BMs followed by osimertinib (Upfront LT group) and pts who received osimertinib without upfront LT (Osimertinib alone group). Overall survival (OS) and central nervous system progression free survival (CNS-PFS) between the two groups were compared. Inverse probability treatment weighting (IPTW) analysis with propensity scores was performed to adjust for potential confounding factors.
Results
A total of 121 pts was enrolled: median (range) age 72 (40–89) years; 83 (69%) female; 92 (76%) ECOG PS 0–1, 29 (24%) PS 2–4; 116 (96%) adenocarcinoma; EGFR status 57 (47%) 19del, 64 (53%) L858R; number of BMs 37 (31%) single, 84 (69%) multiple; median (range) maximum size of BMs 10 (1–51) mm; Symptoms of BMs 26 (21%) yes, 95 (79%) no; 45 (37%) upfront LT, 76 (63%) osimertinib alone. IPTW-adjusted Kaplan-Meier curves showed that OS of pts in the upfront LT group was significantly longer than that of pts in osimertinib alone group (median, Not reached (NR); 95% CI, NR–NR versus median, 31.2 months; 95%CI, 21.7–33.2; p=0.021). IPTW-adjusted HR for OS was 0.37 (95%CI, 0.16–0.87). IPTW-adjusted HR for CNS-PFS was 0.36 (95%CI, 0.15–0.87).
Conclusions
These results suggest that upfront LT for BMs followed by osimertinib may improve survival for pts with EGFR-mt NSCLC despite the high CNS activity of osimertinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Tozuka: Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K.. R. Noro: Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Chugai Pharmaceutical, AstraZeneca, Merck Pharmaceutical, Pfizer Pharmaceutical, Meijiseika Pharmaceutical, GSK Pharmaceutical, Daiichi Sankyo Pharmaceutical; Financial Interests, Personal and Institutional, Funding: the Promotion of Joint International Research (Fostering Joint International Research), and Grant-in-Aid for Scientific Research (C). T. Hakozaki: Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Chugai Pharmaceutical, Eisai, Ono Pharmaceutical. T. Naito: Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca. Y. Hosomi: Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squibb, Kyowa Kirin , Nippon Kayaku, Takeda, Eisai , Novartis, Pfizer. T. Hirose: Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca K.K.. T. Okano: Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd. AstraZeneca K.K. Bristol Myers Squibb K.K. Eli Lilly Japan K.K. Takeda Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Bristol Myers Squibb K.K., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Ltd; Financial Interests, Personal, Expert Testimony: Pharmaceuticals and Medical Devices Agency. M. Seike: Financial Interests, Personal and Institutional, Other, Grants or contracts from any entity: Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Nippon Boehringer Ingelheim, Nippon Kayaku, Kyowa Hakko Kirin; Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca, MSD K.K, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Bristol Myers Squibb, Nippon Boehringer Ingelheim, Pfizer, Novartis, Takeda Pharmaceutical, Kyowa Hakko Kirin, Nippon Kayaku, Daiichi Sankyo Company, Merck Biopharma, Amgen inc. All other authors have declared no conflicts of interest.
Resources from the same session
1342P - Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
Presenter: Guangchuan Deng
Session: Poster session 19
1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Presenter: Bilal Krayim
Session: Poster session 19
1344P - A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
Presenter: Jorge Nieva
Session: Poster session 19
1345P - Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
Presenter: Melissa Junttila
Session: Poster session 19
1346P - Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
Presenter: Xiaoyan Li
Session: Poster session 19
1348P - Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies
Presenter: Yun-Gyoo Lee
Session: Poster session 19
1349P - Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
Presenter: Molly Li
Session: Poster session 19
1351P - Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Presenter: Dan Tao
Session: Poster session 19
1352P - Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC
Presenter: Ruyun Gao
Session: Poster session 19